Publications

Engineered E. coli as Vehicles for Targeted Therapeutics.
Curr Gene Ther. 2010 Feb;10(1):27-33.

Describes the utility of engineered bacteria as carrier for therapeutics and discusses the necessary regulatory pathway with the Food and Drug Administration (FDA).

 

Delivery of short hairpin RNAs by transkingdom RNA interference modulates the classical ABCB1-mediated multidrug-resistant phenotype of cancer cells.
Cell Cycle. 2009 Oct 15;8(20):3349-3354.

Describes the innovative use of transkindom RNAi to break chemotherapy resistance by silencing mdr-1.

 

Transkingdom RNA interference (tkRNAi as a new delivery tool for therapeutic RNA.
Expert Opin Biol Ther. 2009 Dec;9(12):1533-42.

Discussion of tkRNAi and bmRNAi by outside expert.

 

Bacterial vectors and delivery systems in cancer therapy. IDrugs, 2010 Oct; 13(10):701-6

Description and overview of various bacterial therapeutic strategies.